[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncology-patients-receiving-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncology-patients-receiving-chemotherapy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100643563","phase-3-olanzapine-in-the-prevention-and-treatment-of-anorexia-cachexia-syndrome-in-patients-receiving-neoadjuvantpreoperative-chemotherapy-100643563",false,"NCT07633236","Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant\u002FPreoperative Chemotherapy","Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients With Localized and Locally Advanced Tumors Receiving Neoadjuvant\u002FPreoperative Chemotherapy","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG status 0-2\n* Localized\u002Flocally advanced ovarian or gastric cancer requiring neoadjuvant\u002Fpreoperative chemotherapy followed by surgery\n* Ability to consume food\u002Fmedications orally\n\nExclusion Criteria:\n\n* Olanzapine use (\\>4 days) for other indications at enrollment\n* Current use of antipsychotics\u002Fantidepressants\n* Systemic corticosteroid use (\\>7 days within the last 4 weeks)\n* History of psychiatric disorders","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients. The main questions it aims to answer are:\n\nIs prolonged low-dose olanzapine effective and save in:\n\n* Preventing\u002Ftreating weight loss due to anorexia.\n* Controlling nausea\u002Fvomiting.\n* Maintaining anticancer therapy dose intensity?\n\nDoes prolonged low-dose olanzapine improve quality of life in patients receiving neoadjuvant\u002Fpreoperative chemotherapy?\n\nParticipants will:\n\nTake prolonged low-dose olanzapine (2.5 mg\u002Fday) in treatment group or usual diet only in control group until surgical treatment Physical examination, anthropometric assessment, blood tests, quality of life, appetite and nutritional status assessment, abdominal CT, handgrip dynamometry before chemotherapy and after preoperative chemotherapy before surgery Physical examination, adverse events every visit Surgical complications within 30 days after surgery",[25,26,27],"Oncology Patients Receiving Chemotherapy","Cachexia-Anorexia Syndrome","Oncology","RECRUITING","2026-06-03",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":32},"2025-03-28",{"date":36,"type":19},"2027-05-31",{"name":38,"class":39},"Blokhin's Russian Cancer Research Center","OTHER"]